Description

Orexin A 5mg – Hypocretin-1 Neuropeptide Research

Orexin A 5mg is a neuropeptide research product containing a labelled quantity of 5mg of Orexin-A, also known as Hypocretin-1. Orexin-A is a naturally occurring 33-amino-acid peptide involved in the regulation of wakefulness, arousal, hypothalamic signalling and energy-related physiological processes.

Orexin A belongs to the orexin/hypocretin neuropeptide family, which consists of two mature signalling peptides: Orexin-A and Orexin-B. Both are produced from the precursor protein prepro-orexin, encoded by the HCRT gene.

Scientific investigations have examined Orexin-A in relation to orexin receptor activation, sleep–wake regulation, neuronal excitability, feeding behaviour, motivation and the biological mechanisms underlying narcolepsy.

The mature Orexin-A molecule contains an N-terminal pyroglutamyl residue, two intramolecular disulfide bridges and a C-terminal amide. These structural characteristics distinguish it from Orexin-B and are important for biochemical identification.

Orexin A 5mg is intended for laboratory research. Although the endogenous orexin system is essential for normal wakefulness regulation, this does not establish that externally supplied Orexin-A is a safe or effective treatment for fatigue, narcolepsy, obesity or cognitive impairment.

What Is Orexin A 5mg?

Orexin A 5mg refers to a research preparation labelled as containing 5 milligrams of the neuropeptide Orexin-A.

Orexin-A, also called Hypocretin-1, is a peptide signalling molecule produced by neurons located primarily in the lateral hypothalamus and adjacent regions.

Orexin-producing neurons project to multiple areas of the central nervous system and participate in the regulation of behavioural state.

The orexin system helps maintain stable wakefulness and influences interactions between arousal, motivation and energy availability.

Orexin-A acts through two principal G-protein-coupled receptors: orexin receptor type 1 (OX1R) and orexin receptor type 2 (OX2R).

Its scientific importance extends to neuroscience, sleep research, receptor pharmacology and neuroendocrine signalling.

Orexin A 5mg Product Specifications

• Product Name: Orexin A 5mg
• Scientific Name: Orexin-A
• Alternative Names: Hypocretin-1, Orexin-A peptide
• Classification: Endogenous neuropeptide
• Peptide Family: Orexin/Hypocretin
• Peptide Length: 33 amino acid residues
• Reference Sequence: pGlu-PLPDCCRQKTCSCRLYELLHGAGNHAAGILTL-NH2
• Disulfide Bonds: Cys6–Cys12 and Cys7–Cys14
• N-Terminal Modification: Pyroglutamate
• C-Terminal Modification: Amidation
• Reference Molecular Formula: C152H243N47O44S4
• Reference Molecular Weight: Approximately 3,561.1 g/mol
• Reference CAS Number: 205599-75-3
• PubChem CID: 56842143
• Precursor Protein: Prepro-orexin
• Associated Gene: HCRT
• Primary Receptors: OX1R and OX2R
• Research Category: Neuroscience and neuropeptide biochemistry
• Primary Research Focus: Sleep–wake regulation and arousal signalling
• Additional Research Focus: Hypothalamic signalling, neuronal excitability and energy homeostasis
• Labelled Quantity: 5mg
• Purity: Requires batch-specific verification
• Salt Form: Confirm with manufacturer
• Physical Form: Confirm with manufacturer
• Storage: Follow verified manufacturer instructions
• Intended Use: Laboratory research only

These specifications describe the reference Orexin-A molecule. Commercial research preparations may differ in salt form, counterion composition, purity and physical presentation. Batch-specific documentation should be used to confirm the identity and composition of the supplied material.

Orexin A Amino Acid Sequence and Molecular Structure

Orexin-A is a 33-amino-acid peptide with a highly conserved molecular structure among mammals.

Its reference sequence is:

pGlu-PLPDCCRQKTCSCRLYELLHGAGNHAAGILTL-NH2

The N-terminal residue is pyroglutamate, a cyclic form derived from glutamine.

The peptide also contains two intramolecular disulfide bonds:

• First Disulfide Bridge: Cys6–Cys12
• Second Disulfide Bridge: Cys7–Cys14

These bonds help stabilise the three-dimensional structure of the peptide.

The C-terminal leucine residue is amidated, another important structural feature.

Researchers should verify the correct disulfide connectivity, terminal modifications and molecular mass when evaluating Orexin A 5mg.

How Does Orexin A Work?

Orexin-A functions as an endogenous signalling molecule in the central nervous system.

Its effects are mediated through two principal receptors: OX1R and OX2R.

Both receptors belong to the G-protein-coupled receptor family.

Orexin-A activates both receptor subtypes with relatively high potency.

Receptor activation can influence intracellular calcium signalling, neuronal excitability and communication between brain regions involved in wakefulness and behavioural regulation.

The resulting physiological effects depend on receptor distribution, cellular context and interactions with other neurotransmitter systems.

However, receptor activation observed in laboratory systems does not establish the clinical effectiveness of externally administered Orexin-A.

Scientific Research Into Orexin A 5mg

1. Orexin A 5mg and Sleep–Wake Regulation

The sleep–wake cycle depends on interactions among multiple neuronal networks.

Orexin-producing neurons are important components of the brain’s wakefulness-promoting circuitry.

Orexin-A contributes to signalling that helps stabilise transitions between wakefulness and sleep.

Research into the orexin system has demonstrated its importance in maintaining behavioural state.

However, this does not establish that Orexin A 5mg is a clinically effective treatment for excessive daytime sleepiness.

2. Orexin A and Hypocretin-1 Research

Orexin-A and Hypocretin-1 are two names for the same mature neuropeptide.

The terms originated from independent research programmes that identified the orexin/hypocretin system in 1998.

Both terms remain common in neuroscience literature.

Researchers should distinguish Hypocretin-1 from Hypocretin-2, which is another name for Orexin-B.

3. Orexin A 5mg and OX1R Signalling

Orexin receptor type 1, abbreviated OX1R, is a G-protein-coupled receptor activated by Orexin-A.

OX1R is expressed in selected neuronal populations and participates in several orexin-related signalling pathways.

Researchers investigate OX1R to understand receptor activation, neuronal communication and behavioural responses.

However, receptor activity alone does not establish a therapeutic benefit.

4. Orexin A and OX2R Research

Orexin receptor type 2, abbreviated OX2R, is another principal receptor within the orexin system.

Both Orexin-A and Orexin-B can activate OX2R.

OX2R signalling is particularly important in research into wakefulness regulation and narcolepsy.

Experimental investigations have examined how activation or inhibition of OX2R influences sleep–wake stability.

5. Orexin A 5mg and Hypothalamic Research

The hypothalamus regulates numerous physiological functions, including sleep, feeding, temperature and endocrine activity.

Orexin-producing neurons are concentrated in hypothalamic regions and project widely throughout the brain.

These projections allow orexin signalling to influence multiple neuronal networks.

Orexin-A research contributes to understanding how hypothalamic signals coordinate arousal and behavioural state.

6. Orexin A and Neuronal Excitability

Neuronal excitability describes the capacity of neurons to respond to stimulation and generate electrical signals.

Orexin receptor activation can alter neuronal excitability through intracellular signalling pathways.

Researchers have investigated orexin-related responses in several neuronal populations.

However, the effects depend on receptor subtype, brain region and experimental conditions.

7. Orexin A 5mg and Narcolepsy Research

Narcolepsy type 1 is strongly associated with loss of orexin-producing neurons and deficient orexin signalling.

Research involving Orexin-A has contributed to understanding the biological mechanisms underlying this disorder.

Measurement of hypocretin-1 in cerebrospinal fluid is also relevant to clinical diagnostic evaluation in appropriate settings.

However, these findings do not establish that a commercial Orexin A 5mg research preparation is suitable for treating narcolepsy.

Investigational receptor agonists and other treatment approaches require separate clinical evaluation.

8. Orexin A and Feeding Behaviour Research

The orexin peptides were originally investigated partly because of their effects on feeding behaviour in animal models.

Orexin-A has been studied in relation to appetite, food-seeking behaviour and neural responses to energy availability.

However, feeding behaviour is regulated by numerous interacting neural and hormonal systems.

Experimental feeding responses should not be interpreted as evidence that Orexin-A is an effective human weight-loss treatment.

9. Orexin A 5mg and Energy Homeostasis

Energy homeostasis involves the regulation of energy intake, expenditure and storage.

Orexin signalling interacts with neural circuits involved in metabolic state and behavioural activity.

Researchers have investigated relationships between orexin signalling, feeding, locomotion and energy expenditure.

However, these relationships are complex and do not establish a predictable effect of externally administered Orexin-A on body weight.

10. Orexin A and Motivation Research

Orexin-related signalling has been investigated in brain circuits involved in motivation and reward.

These pathways interact with arousal and behavioural state regulation.

Animal studies have examined orexin-related responses to environmental cues and rewarding stimuli.

However, these observations do not establish that Orexin-A improves motivation or mental performance in humans.

11. Orexin A 5mg and Stress-Related Signalling

Physiological stress responses involve interactions among neural, autonomic and endocrine systems.

Orexin signalling has been investigated in several of these pathways.

Researchers have examined how orexin receptor activation influences arousal and stress-associated responses.

However, the available evidence does not establish a therapeutic role for Orexin A 5mg in anxiety or stress disorders.

12. Orexin A and Circadian Biology

Circadian rhythms influence daily patterns of sleep, activity and hormone secretion.

The orexin system interacts with networks involved in maintaining wakefulness across the day.

However, Orexin-A is not itself the central circadian clock.

Researchers distinguish circadian timing from the neuronal systems that regulate arousal and sleep–wake stability.

13. Orexin A 5mg and Peptide Structure Research

The molecular structure of Orexin-A includes two disulfide bonds and modified terminal residues.

These features distinguish it from Orexin-B and many other neuropeptides.

Researchers have investigated how peptide structure influences orexin receptor activation.

Structure-activity relationship studies can help identify molecular regions important for receptor binding and signalling.

14. Orexin A and Receptor Pharmacology

Receptor pharmacology investigates how signalling molecules interact with biological targets.

Orexin-A is an important reference ligand in experimental studies of OX1R and OX2R.

Researchers may use receptor-binding and functional assays to investigate receptor activation and downstream signalling.

These studies contribute to the development of compounds designed to modulate the orexin system.

15. Orexin A 5mg and Research Reproducibility

Reliable neuropeptide research requires accurately characterised experimental materials.

Researchers should verify the complete 33-amino-acid sequence, N-terminal pyroglutamate, C-terminal amidation and correct disulfide connectivity.

Differences in purity, salt form, oxidation state and formulation may influence experimental results.

Batch-specific analytical documentation supports reproducibility.

Orexin A 5mg vs Orexin B 5mg

Orexin-A and Orexin-B are different neuropeptides produced from the same precursor protein.

• Orexin A: Contains 33 amino acid residues.
• Orexin B: Contains 28 amino acid residues.
• Orexin A Structure: Includes an N-terminal pyroglutamate, two disulfide bonds and C-terminal amidation.
• Orexin B Structure: Is a linear peptide with C-terminal amidation and no intramolecular disulfide bonds.
• Receptor Activity: Orexin-A activates both OX1R and OX2R with high potency; Orexin-B generally shows greater relative potency at OX2R.
• Research Interpretation: Results involving one peptide should not automatically be attributed to the other.

Orexin A 5mg vs Orexin Receptor Agonists

Orexin-A is a naturally occurring peptide agonist of orexin receptors.

Investigational orexin receptor agonists may have different molecular structures, receptor selectivity and pharmacokinetic properties.

Some experimental compounds are designed to activate OX2R selectively.

Clinical evidence involving these investigational compounds should not be used as proof of the safety or effectiveness of Orexin A 5mg.

Orexin A 5mg vs Orexin Receptor Antagonists

Orexin receptor antagonists block signalling through orexin receptors.

They are pharmacologically different from Orexin-A, which activates these receptors.

Some orexin receptor antagonists are approved medicines for insomnia in certain jurisdictions.

However, their clinical evidence does not establish any therapeutic benefit for externally supplied Orexin-A peptide.

Orexin A 5mg and Weight-Loss Claims

Orexin signalling has been investigated in relation to feeding behaviour and energy homeostasis.

However, the relationship between orexin activity and body weight is complex.

There is insufficient reliable human clinical evidence demonstrating that Orexin A 5mg safely reduces body fat or treats obesity.

It should not be marketed as a proven weight-loss peptide or fat-burning treatment.

Orexin A 5mg and Wakefulness Claims

The endogenous orexin system plays a central role in maintaining wakefulness.

However, this does not establish that externally administered Orexin A 5mg is a safe or effective treatment for fatigue or excessive daytime sleepiness.

Peptide delivery, central nervous system exposure, receptor activation and clinical safety require separate investigation.

Orexin A 5mg Research Quality and Documentation

Important considerations when evaluating Orexin A 5mg include:

• Verification of the complete 33-amino-acid sequence
• Confirmation of N-terminal pyroglutamate
• Verification of C-terminal amidation
• Confirmation of Cys6–Cys12 disulfide connectivity
• Confirmation of Cys7–Cys14 disulfide connectivity
• Verification of the expected molecular mass
• Identification of the supplied salt form
• Batch-specific certificate of analysis
• Appropriate analytical purity testing
• Mass spectrometry or another suitable identity method
• Confirmation of the labelled 5mg quantity
• Assessment of synthesis-related impurities
• Manufacturer and batch traceability
• Documentation of formulation components
• Product-specific storage and stability information
• Clearly stated research-use classification

Storage and Handling of Orexin A 5mg

Orexin A 5mg should be stored according to verified manufacturer instructions.

Storage requirements depend on peptide formulation, salt form, packaging and stability characteristics.

Researchers should not assume that all Orexin-A preparations have identical storage requirements or shelf lives.

Laboratory handling should follow institutional procedures and product-specific safety documentation.

Orexin A 5mg Safety and Scientific Limitations

Orexin A 5mg is a research material without an established human therapeutic safety or effectiveness profile.

Important uncertainties include pharmacokinetics, central nervous system exposure, receptor activity outside the intended experimental target and the consequences of repeated exposure.

Because orexin signalling participates in arousal, autonomic function and other physiological processes, altering this system may have effects beyond wakefulness alone.

There is insufficient reliable evidence demonstrating safe and effective human use for weight loss, fatigue, narcolepsy or cognitive enhancement.

Orexin-A is not an established approved UK medicine for these purposes.

Research-grade material should not be assumed suitable for human administration.

The labelled 5mg quantity is not a human dosing recommendation.

Frequently Asked Questions About Orexin A 5mg

What is Orexin A 5mg?

Orexin A 5mg is a product designation for the 33-amino-acid neuropeptide Orexin-A, also known as Hypocretin-1, with a labelled quantity of 5mg.

What is another name for Orexin A?

Orexin-A is also known as Hypocretin-1.

How many amino acids does Orexin A contain?

Orexin-A contains 33 amino acid residues.

What is the Orexin A peptide sequence?

The reference sequence is pGlu-PLPDCCRQKTCSCRLYELLHGAGNHAAGILTL-NH2, with disulfide bonds between Cys6–Cys12 and Cys7–Cys14.

What is the molecular formula of Orexin A?

The reference molecular formula is C152H243N47O44S4.

What is the molecular weight of Orexin A?

The reference molecular weight is approximately 3,561.1 g/mol.

What is the CAS number for Orexin A?

The commonly referenced CAS number is 205599-75-3.

Is Orexin A the same as Orexin B?

No. Orexin-A contains 33 amino acids and two disulfide bonds, while Orexin-B contains 28 amino acids and lacks disulfide bonds.

Which receptors does Orexin A activate?

Orexin-A activates the orexin receptors OX1R and OX2R.

Is Orexin A involved in sleep regulation?

Yes. The orexin system is important in maintaining wakefulness and stabilising sleep–wake transitions.

Is Orexin A a treatment for narcolepsy?

No. A commercial Orexin-A research peptide is not an established approved treatment for narcolepsy.

Does Orexin A help with weight loss?

There is insufficient reliable human clinical evidence demonstrating that Orexin-A safely produces weight loss.

Is Orexin A approved for human use?

Orexin-A is not an established approved UK medicine for sleep disorders, weight management or cognitive enhancement.

What does Orexin A 5mg mean?

The designation refers to a labelled quantity of 5mg of research material, not a recommended human dose.

Orexin A 5mg – Scientific Product Summary

Orexin A 5mg is a research product designation for the endogenous 33-amino-acid neuropeptide Orexin-A, also known as Hypocretin-1.

Its reference molecular structure includes an N-terminal pyroglutamate, two intramolecular disulfide bonds and C-terminal amidation.

Published research has investigated Orexin-A in relation to OX1R and OX2R signalling, sleep–wake regulation, hypothalamic function, neuronal excitability and energy homeostasis.

However, these scientific findings do not establish human therapeutic effectiveness or long-term safety.

Researchers evaluating Orexin A 5mg should verify molecular identity, disulfide connectivity, purity, formulation, labelled quantity and batch-specific analytical documentation.